By John Carroll Designing a better antibody is one of the hottest strategies driving start-up biotechs in the U.S. And one recent entry in the field has picked up a pair of powerhouse venture backers. This morning CytomX Therapeutics announced that it banked $30 million from a Series B led by Third Rock Ventures and …
By John Carroll Boston-based Third Rock Ventures, one of the busiest and best connected biotech investors in the business, has raised $426 million for its second fund and has officially announced plans for a West Coast office. Former Portola CEO Charles Homcy will take over as the partner in charge of the San Francisco office and Alexis Borisy, who …
By John Carroll Third Rock Ventures, an aggressive investor in biotech startups that promise to develop game-changing technology, is out raising a new $400 million fund. And the news hit on the same day Third Rock announced it is leading a $25 million Series A for Foundation Medicine–a new biotech player led by a well-known …
